Depression alert in China indicates opportunity for Pharma companies

Depression is now considered the second most severe psychiatric disease in the world next to Alzheimer's disease, which brings tremendous burden to families and nations, according to Ping Wu, district manager of Kanghong Pharmaceutical Group. He said at the 3rd International Medical Expo (Taizhou), ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research

Biofourmis and Chugai look toward digital women's health, partnering to develop biomarkers for endometriosis

Case Study | April 20, 2021

In 2020, Biofourmis and Chugai Pharmaceutical partnered to develop an analytics platform for quantifying pain associated with endometriosis. Biofourmis is a global leader in AI‑driven digital therapeutics, and Chugai is a leading Japanese pharmaceutical research company. The platform consists of a ... Not part of subscription

Digital therapeutic Akili Interactive Labs to study effects of product on COVID-19 brain fog

News Commentary | April 15, 2021

As the immediate life‑threatening concerns of COVID‑19 begin to wane due to vaccines, there is a growing need to address the long‑term health impacts of the pandemic. Cognitive deficits, especially brain fog, are emerging as a common long‑term symptom. Akili is exploring its current offering for ... Not part of subscription

Blue Spark's wearable device to be used in CAR T cell therapy trial, enabling continuous remote monitoring for side effects

News Commentary | June 07, 2021

Blue Spark Technologies announced that its TempTraq wearable Bluetooth continuous body temperature monitoring device will be used across all of Bristol Myers Squibb's (BMS) CAR T therapies before and during CAR T patients' infusion with the cell therapy. Fever is predictive of cytokine release ... Not part of subscription